View Exam | PowerPak

1. Which of the following patients are MOST likely to benefit from initiating a GLP-1 RA/insulin fixed-dose combination product?

A. Patients taking large doses of basal insulin (greater than 60 units per day) who are unable to achieve their A_1c goal. B. Patients concerned about weight gain and the number of daily insulin injections C. Patients with a history of pancreatitis D. Patients with dexterity issues that have trouble with insulin pens and needles

2. SJ is a 62-year-old woman with a 4-year history of type 2 diabetes for which she is currently taking metformin 1000 mg twice daily and insulin glargine 30 units daily. Her most recent A_1c level was 8.2%. Since starting basal insulin 2 years ago, she has gained 12 lbs, and her current body mass index is 33 kg/_m2. She states that she adheres to her medication regimen and only misses a dose once or twice a month. She is frustrated with her diabetes, is concerned about weight gain and risks of hypoglycemia, and does not want to add any more injections to her regimen. Which of the following pharmacotherapy options would be MOST appropriate to recommend to SJ's physician to achieve a target A_1c lower than 7%?

A. Add a sulfonylurea to her diabetes regimen B. Increase SJ's basal insulin dose by 10% to 20% to achieve fasting blood glucose range between 70 to 130 mg/dL C. Initiate rapid-acting insulin with each meal D. Use a combination GLP-1 RA/fixed dose insulin product or add a once weekly GLP-1 RA

3. All of the following statements describe results of the DUAL-VII trial, which compared fixed dose combination liraglutide/insulin glargine to a basal/bolus insulin glargine/insulin aspart, EXCEPT?

A. Liraglutide/insulin glargine is associated with weight loss profile when compared to insulin glargine/insulin aspart. B. Liraglutide/insulin glargine is associated with a reduced incidence of hypoglycemia when compared to an insulin glargine/insulin aspart regimen. C. Liraglutide/insulin glargine is associated with greater reductions in A_1c when compared to an insulin glargine/insulin aspart regimen. D. Patients utilizing liraglutide/insulin glargine used a lower total daily dose of insulin compared to insulin glargine/insulin aspart users.

4. When counseling a patient initiated on combination product insulin glargine/lixisenatide after being inadequately controlled on 30 to 60 units of basal insulin, what is the appropriate dosing and administration schedule?

A. 20 units (20 units insulin glargine/10 mcg lixisenatide) given subcutaneously once daily B. 20 units (20 units insulin glargine/10 mcg lixisenatide) given subcutaneously twice daily C. 30 units (30 units insulin glargine/10 mcg lixisenatide) given subcutaneously once daily D. 30 units (30 units insulin glargine/10 mcg lixisenatide) given subcutaneously twice daily

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following patients are MOST likely to benefit from initiating a GLP-1 RA/insulin fixed-dose combination product?

3. All of the following statements describe results of the DUAL-VII trial, which compared fixed dose combination liraglutide/insulin glargine to a basal/bolus insulin glargine/insulin aspart, EXCEPT?

4. When counseling a patient initiated on combination product insulin glargine/lixisenatide after being inadequately controlled on 30 to 60 units of basal insulin, what is the appropriate dosing and administration schedule?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following patients are MOST likely to benefit from initiating a GLP-1 RA/insulin fixed-dose combination product?

3. All of the following statements describe results of the DUAL-VII trial, which compared fixed dose combination liraglutide/insulin glargine to a basal/bolus insulin glargine/insulin aspart, EXCEPT?

4. When counseling a patient initiated on combination product insulin glargine/lixisenatide after being inadequately controlled on 30 to 60 units of basal insulin, what is the appropriate dosing and administration schedule?

« Return to Activity

Customers who Purchased
this Activity also Purchased